Armistice Capital’s AstraZeneca AZN Stock Holding History

Armistice Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,500	Closed	-$3.28M	–	339
2025 Q2	$3.28M	Buy	23,500 +11,500	+96%	+$1.61M	0.06%	114
2025 Q1	$1.76M	Sell	12,000 -38,000	-76%	-$5.5M	0.03%	151
2024 Q4	$6.55M	Buy	+50,000	New	+$7M	0.09%	116
2022 Q3	–	Sell	-418,000	Closed	-$55.2M	–	201
2022 Q2	$55.2M	Buy	418,000 +122,000	+41%	+$16M	0.96%	27
2022 Q1	$39.3M	Buy	296,000 +96,000	+48%	+$11.5M	0.76%	40
2021 Q4	$23.3M	Buy	+200,000	New	+$23.5M	0.38%	56

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Armistice Capital's AZN Position: Q3 2025 in Review

Armistice Capital sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 23,500 shares — an estimated $3.28M sold.

Armistice Capital first reported a position in AZN in Q4 2021 and held it in 6 quarters. The position peaked at $55.2M in Q2 2022. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

Armistice Capital reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 23,500 AstraZeneca shares in Q3 2025, an estimated $3.28M.
Armistice Capital first reported a position in AstraZeneca in Q4 2021 and held it in 6 quarters.
Armistice Capital's AstraZeneca position peaked at $55.2M in Q2 2022.
1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.